123 related articles for article (PubMed ID: 28345820)
1. Meta-Analysis of Serum Gastrin-Releasing Peptide Precursor as a Biomarker for Diagnosis of Small Cell Lung Cancer.
Lv ShP; Wang Y; Huang L; Wang F; Zhou JG; Ma H
Asian Pac J Cancer Prev; 2017 Feb; 18(2):391-397. PubMed ID: 28345820
[TBL] [Abstract][Full Text] [Related]
2. Serum pro-gastrin-releasing peptide in diagnosis of small cell lung cancer: A meta-analysis.
Wang H; Qian J
J Cancer Res Ther; 2016 Dec; 12(Supplement):C260-C263. PubMed ID: 28230031
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer.
Gong Z; Lu R; Xie S; Jiang M; Liu K; Xiao R; Shen J; Wang Y; Guo L
Biochem Biophys Res Commun; 2016 Oct; 479(2):312-318. PubMed ID: 27639644
[TBL] [Abstract][Full Text] [Related]
4. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of ProGRP and NSE for small cell lung cancer: a meta-analysis].
WANG J; GAO J; HE J
Zhongguo Fei Ai Za Zhi; 2010 Dec; 13(12):1094-100. PubMed ID: 21159242
[TBL] [Abstract][Full Text] [Related]
6. Clinical Application of Pro-Gastrin-Releasing Peptide.
Fang L; Huang Z; Lin Y; Fu J; Liang X; Liu F
Clin Lab; 2018 Jul; 64(7):1259-1268. PubMed ID: 30146822
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of pro-gastrin-releasing peptide for small cell lung cancer: a meta-analysis.
Yang HJ; Gu Y; Chen C; Xu C; Bao YX
Clin Chem Lab Med; 2011 Jun; 49(6):1039-46. PubMed ID: 21649553
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of tumor marker pro-gastrin-releasing peptide in patients with small cell lung cancer: a systematic review.
Tang JH; Zhang XL; Zhang ZH; Wang R; Zhang HM; Zhang ZL; Wang JH; Ren WD
Chin Med J (Engl); 2011 May; 124(10):1563-8. PubMed ID: 21740817
[TBL] [Abstract][Full Text] [Related]
9. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer.
Oh HJ; Park HY; Kim KH; Park CK; Shin HJ; Lim JH; Kwon YS; Oh IJ; Kim YI; Lim SC; Kim YC; Kim SH; Shin MG
J Thorac Dis; 2016 Sep; 8(9):2530-2537. PubMed ID: 27747005
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic and prognostic value of ProGRP in lung cancer.
Nisman B; Biran H; Ramu N; Heching N; Barak V; Peretz T
Anticancer Res; 2009 Nov; 29(11):4827-32. PubMed ID: 20032442
[TBL] [Abstract][Full Text] [Related]
11. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
12. [A clinical study of ProGRP as a new tumor marker for small cell lung cancer].
Yu B; Liu Q; Chen L
Zhongguo Fei Ai Za Zhi; 2003 Jun; 6(3):209-10. PubMed ID: 21266123
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic value of ProGRP for small cell lung cancer in different stages.
Dong A; Zhang J; Chen X; Ren X; Zhang X
J Thorac Dis; 2019 Apr; 11(4):1182-1189. PubMed ID: 31179060
[TBL] [Abstract][Full Text] [Related]
14. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
15. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
16. Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm.
Rosiek V; Kogut A; Kos-Kudła B
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444393
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of chemiluminescent immunoassay quantitative detection for pro-gastrin-releasing peptide (ProGRP) in serum and plasma.
Cheng Y; He J; Zhang L; Chen X; Ou S
J Int Med Res; 2020 Apr; 48(4):300060519882802. PubMed ID: 31856626
[TBL] [Abstract][Full Text] [Related]
18. Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer.
Uchida K; Kojima A; Morokawa N; Tanabe O; Anzai C; Kawakami M; Eto Y; Yoshimura K
J Cancer Res Clin Oncol; 2002 Dec; 128(12):633-40. PubMed ID: 12474049
[TBL] [Abstract][Full Text] [Related]
19. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
20. Pro-gastrin-releasing peptide in patients with benign and malignant diseases.
Molina R; Auge JM; Alicarte J; Filella X; Viñolas N; Ballesta AM
Tumour Biol; 2004; 25(1-2):56-61. PubMed ID: 15192313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
